Full TitleA Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies
The purpose of this study is to evaluate the safety and preliminary effectiveness of the immunotherapy drug MK-3475 (pembrolizumab) in patients with myelodysplastic syndromes (MDS), Hodgkin lymphoma, and non-Hodgkin lymphoma whose disease has persisted or returned despite treatment with previous therapy. MK-3475 is a protein called an antibody which binds to PD-1, a protein on T cells (a type of white blood cell).
It is hoped that when MK-3475 binds to PD-1, it will “turn on” the T cells and cause the immune system to detect and destroy cancer cells. MK-3475 is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have MDS, Hodgkin lymphoma, or non-Hodgkin lymphoma that has either not responded to standard therapy or has come back despite prior treatment.
- Any serious side effects of previous therapies should have resolved by the time the patient enters the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities.
- This study is open to patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Martin Tallman at 212-639-3842.